Faes Farma increases its revenue by more than 15% to €454 million

• The company exceeds its revenue forecasts for the year as a whole thanks to the strong performance across all business areas

• The Pharma division posts double-digit growth (+13%) driven by strong performance in both Latin America (+16%) and licensing (+17%)

• Adjusted EBITDA exceeds €112 million (+3%), in line with guidance

• The company is making steady progress in the execution of its Strategic Plan with the advancement of the integrations of Laboratorios Edol and SIFI

Bilbao, 4 November 2025. – The Faes Farma Group today presented its results for the first nine months of 2025. Between January and September, the company’s revenue grew by 15.5% to €454 million, exceeding the announced guidance, thanks to strong performance across all business areas.

Specifically, revenues for the Pharma division rose by more than 13% in the first nine months of the year to €399.5 million, thanks to strong performance in the Latin American market (+16%) and licensing (+17%). Meanwhile, revenues from FARM Faes, the Animal Nutrition division, recorded strong growth (+48%) to €57.8 million, with the ISF business (new plant in Huesca) as the main driver.

Revenue from the three strategic molecules – Bilastine, Calcifediol and Mesalazine – continues to grow strongly, rising by more than +15% overall. Specifically, Bilastine revenue improved by +11%, while Calcifediol and Mesalazine revenue increased by +15% and +59%, respectively.

Adjusted EBITDA for the period reached €112.8 million, representing an increase of +3%, in line with expectations. This figure does not include the extraordinary and one-off costs of Derio or the results derived from the recent acquisitions of Laboratorio Edol and SIFI. Reported EBITDA amounted to €106.5 million (-2.7%), exceeding the most positive range of the guidance announced for the year (-6/-9%). Likewise, net profit for the first nine months of the year reached €73.6 million, representing a decrease of 7.6% compared to the same period last year, impacted by both the extraordinary costs of Derio and those associated with M&A operations, in line with expectations.

Growth in all divisions of the Pharma business

In the Iberian Pharmaceuticals business, revenues reached €170.7 million (+8%), driven mainly by the performance of prescription products (medical visits), as well as the incorporation of Laboratorio Edol in Portugal in June.

Revenues from international markets totalled €129.6 million in this period (+19%). The Latin American region continued to perform well, contributing €83.8 million, as did the rest of the international countries, with €45.8 million. In Latin America, Colombia (+25%), Ecuador (+31%) and Peru (+25%) continue to perform very positively based on the strategy to maximise Bilastina and Hidroferol products.

Licence income totalled €99.2 million (+17%). Bilastine maintained the solid growth rate seen in the first few months of the year, especially in existing markets (mainly in Eastern Europe and Southeast Asia). Other licences recorded a sharp increase in revenue (+55%), reaching €22.9 million, driven by a significant increase in Mesalazine thanks to strong growth in local sales in Poland (where it has achieved a leading position) and in the Nordic countries. Calcifediol continues its successful expansion in Eastern European markets, where it is already exceeding forecasts. It has also been launched in markets with high growth potential, such as Greece and Australia.

Steady progress in implementing the new Strategic Plan

The announcement of these results also concurs with the first six months of the new 2025-2030 Strategic Plan, which aims to achieve €1 billion in revenue and €240 million in EBITDA. The company is making progress towards this roadmap, as demonstrated by the progress it has made in integrating Laboratorio Edol and SIFI, Portuguese and Italian companies specialising in ophthalmology, respectively, which represent a transformational step in the future of Faes Farma. Thanks to these companies, Faes Farma has one of the most outstanding offerings on the ophthalmology market, strengthening its international position and presence in new markets.

As part of these transactions, the company has signed a bank financing package on favourable economic terms that allows it to maintain its financial strength without altering its dividend policy. In this regard, Faes Farma paid the full dividend for the year in January and July.

Advances in R&D

Innovation is one of Faes Farma’s main drivers and a central element of its Strategic Plan. Proof of this is the company’s efforts to increase its investment in R&D, which involves raising gradually the figure from the current 6% to 10% of the Pharma division’s turnover.

Among the most notable advances during the period was the approval of paediatric Bilastine for children under 6 years of age in Europe, a milestone that expands the therapeutic options for the treatment of allergies in children. In August, the long-awaited evaluation of the dossier for Mesalazine in 1.5 g gastro-resistant tablets by the European regulatory authorities began, and in April the clinical phase of three bioequivalence studies was successfully completed. A new bioequivalence trial was also initiated, consolidating the company’s commitment to research and development of high-quality formulations. Finally, approval was obtained for the reimbursement of Akantior in Spain, which will improve patient access to this treatment within the national health system.

The Faes Farma Group will hold a webcast scheduled for today, 4 November at 10:30 a.m. CET, to explain the main details of the results for the third quarter of 2025. The call will be open and can be accessed via this link:

https://streamstudio.world-television.com/1506-2832-42358/es